The European Commission (EC) has approved Vabysmo® (faricimab) for treating visual impairment caused by macular edema secondary to retinal vein occlusion (RVO), which includes branch RVO and central RVO. This…
Roche announced today the completion of its acquisition of LumiraDx’s Point-of-Care technology, following the necessary antitrust and regulatory approvals. The acquisition will see Roche integrate LumiraDx’s multi-assay point-of-care platform, along…
AbbVie Reports Strong Second-Quarter 2024 Financial Performance AbbVie has announced its financial results for the second quarter ending June 30, 2024. “Our business continues to excel, with second-quarter outcomes significantly…
AbbVie Announces European Approval of SKYRIZI® for Ulcerative Colitis AbbVie has received European Commission approval for SKYRIZI® (risankizumab) to treat adults with moderately to severely active ulcerative colitis (UC) who…
Novo Nordisk has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion on updating the Wegovy® (semaglutide 2.4 mg)…
MSD, known as Merck outside the United States and Canada, has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion…
Autobahn Therapeutics, a biotech firm focused on innovative treatments for neuropsychiatric and neuroimmunologic disorders, has closed an oversubscribed $100 million Series C financing round. The funding was led by Newpath…
PK MED, a French biotech company established in 2019 by Truffle Capital, has secured €1.5 million in non-dilutive DeepTech financing from Bpifrance. This funding will drive the development of PKM-02,…
PROTEINA Co., Ltd., in partnership with Seoul National University (SNU) and Seoul National University Hospital (SNUH), has announced groundbreaking research published in Nature Biomedical Engineering. The study introduces a novel…
Nuvation Bio, a late-stage global biopharmaceutical company focused on oncology, has announced several updates for its taletrectinib program. Data from the global, pivotal Phase 2 TRUST-II study will be presented…
Verastem Oncology, a biopharmaceutical company focused on developing new cancer treatments, announced its intention to offer and sell shares of common stock and accompanying warrants to purchase common stock. The…
Verastem Oncology, a biopharmaceutical company focused on cancer treatments, announced the pricing of an underwritten public offering. The offering includes 13,333,334 shares of common stock and accompanying warrants to purchase…